Simultaneous Recumbent Cycling and Cognitive Training
Launched by UNIVERSITY OF MISSOURI, KANSAS CITY · Sep 14, 2020
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new approach to help middle-aged patients recover from confusion and memory problems (known as delirium) that can occur during their stay in the Intensive Care Unit (ICU). The trial is looking at a program that combines two activities: riding a recumbent bike (a type of exercise bike that you sit back in) while also doing cognitive training exercises (mental tasks to improve thinking skills). The goal is to see if doing these two activities together helps improve brain function and quality of life more than exercising alone.
To participate, individuals should be between 45 and 64 years old, have spent more than 24 hours in a medical or surgical ICU, and experienced at least one episode of delirium during their stay. Participants must be able to speak English, provide consent, and have access to a phone. They will be asked to join sessions at a community rehabilitation center where they can engage in this combined exercise and cognitive training program. The researchers will also gather feedback from participants to see how well they liked the program and if they found it easy to follow. This trial aims to find effective ways to help ICU survivors improve their thinking skills and overall well-being after a challenging hospital experience.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 45-64 years
- • Admitted to medical or surgical ICUs (SLH \& TMC) for \>24 hours
- • English-speaking
- • Discharged home
- • Able to provide consent
- • Access to a telephone
- • One or more delirium episode in ICU (positive CAM-ICU).
- Exclusion Criteria:
- • Cancer diagnosis with short life expectancy determined by the Primary Care Provider (unable to complete the study within time frame)
- • Chemotherapy (drug-induced impaired cognition)
- • Diagnosed vascular dementia or other neurodegenerative diseases (e.g. Alzheimer or Parkinson disease)
- • Documented alcohol consumption ≥5 drinks/day (withdrawal delirium tremens)
- • Corrected vision\<20/80 Snellen chart (unable to do cognitive exercises on the tablet)
- • Examiner rated low hearing or communicative ability that would interfere with intervention and assessments
- • Positive CAM-ICU (delirium) at hospital discharge
- • Unable to participate in rehabilitation (abnormal 6 min walk test)
- • Any physical condition preventing recumbent cycling
- • Recent documented history of drug abuse.
About University Of Missouri, Kansas City
The University of Missouri, Kansas City (UMKC) is a leading academic institution dedicated to advancing health and medical research through innovative clinical trials. With a robust infrastructure that fosters collaboration among multidisciplinary teams, UMKC is committed to enhancing patient care and outcomes by exploring novel therapeutic interventions. The university’s strong emphasis on research excellence and community engagement positions it at the forefront of clinical advancements, ensuring that trials are conducted with the highest ethical standards and scientific rigor. Through its extensive network of healthcare professionals and researchers, UMKC aims to translate research findings into practical applications that benefit diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kansas City, Missouri, United States
Kansas City, Missouri, United States
Patients applied
Trial Officials
Rita S Lasiter, PhD
Principal Investigator
University of Missouri, Kansas City
Matthew S Chrisman, PhD
Principal Investigator
University of Missouri, Kansas City
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials